Depression Drugs Market Trends, 2020-2030

Depression Drugs Market (Drug Class: Selective Serotonin Reuptake Inhibitors [SSRIs], Serotonin and Norepinephrine Reuptake Inhibitors [SNRIs], Atypical Antidepressants, Tricyclic Antidepressants, and Others; Disease Type: Major Depressive Disorder, Schizophrenia and Bipolar I Disorder, Obsessive-Compulsive Disorders [OCD], Anxiety Disorder, and Others; and Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Entry of Novel Pharmacologic and Non-pharmacologic Interventions to Aid Market Growth

Depression today has emerged as a ‘silent killer’ in several regions around the world, particularly in urban cities. The prevalence of depression continues to grow at a rapid pace and has considerably high mortality and morbidity rate due to which, the healthcare sector continues its pursuit for novel medications and therapies. At present, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants among others. Although these drugs have proved to be highly effective, a large number of patients have reported side effects or have not responded to these drugs in the required manner.

However, advancements in the neurobiology of depression over the past few years have opened up new avenues for antidepressant treatment. In addition, in the current depression drugs market, market participants are increasingly focusing on the development of novel non-pharmacologic and pharmacologic interventions. Research and development activities are expected to continue in full swing during the course of the forecast period. In addition, several drug developers are increasingly pinning their hopes to establish a strong presence in the depression drugs market landscape on the FDA to approve their products.

At the back of these factors, along with growing awareness regarding depression, the global depression drugs market is expected to attain a market value of US$ 24.3 Bn by the end of 2030. The evolving regulatory landscape, along with the fast-paced development of new depression medications are likely to influence the overall growth trajectory of the depression drugs market during the assessment period.

depression drugs market infographic

To know the scope of our report Get a Sample on Depression Drugs Market

Research and Development Activities to Remain Key for Market Growth

Major depressive disorder (MDD) continues to remain one of the leading causes of disability around the world. Conventional medications and methods to address depression have repeatedly exhibited a low success rate and are reportedly effective for ~40% patients. These factors have compelled researchers, scientists, and drug developers to explore new pathways that are likely to increase the efficacy of the treatment for major depressive disorder. Research and development activities are likely to influence the overall growth of the depression drugs market. Several research projects around the world are increasingly contributing to the development of novel medications, drugs, and therapies.

For instance, a team of researchers at the Icahn School of Medicine at Mount Sinai, are studying the interleukin-6 molecule– a protein that primarily facilitates communication between different cells. As per the research, individuals suffering from depression have higher levels of IL-6. Another aspect of the research primarily focuses on ezogabine– an anticonvulsant drug that offers immense promise in minimizing symptoms of depression, including low motivation, lack of interest, and inability to feel pressure, among others.

Get a glimpse of the in-depth analysis through our Report Brochure

To date, severe depression is largely treated with tricyclic anti-depressants– a class of drugs that is more effective than other classes of drugs used to address mild to moderate depression. However, the demand for tricyclic anti-depressants is gradually expected to decline due to the side effects associated with them. However, in March 2020, a group of researchers from the University of Copenhagen in collaboration with the National Institutes of Health in Baltimore and Lundbeck A/S has revealed that the team has discovered a potential drug that is likely to ease the side effects of medication that is used to address severe depression.

Market Participants Focus on Attaining FDA Approval for Newly Developed Drugs

Conventional classes of drugs, including monoamine oxidase inhibitors and tricyclic antidepressants have remained popular in the depression drugs market over the past three decades. Over time, the uptake of serotonin reuptake inhibitors, first-generation antipsychotics, and various modern forms of psychotherapy has increased at a rapid pace. Although several pharmaceutical companies have gradually refrained from investing resources in research activities due to continual failure of several trials, several market operators have pinned their hopes on ketamine and various other emerging psychiatric medications. The future of the mental health treatment sector primarily depends on two major factors– investments for drug development & clinical trials and approval from the FDA.

The FDA has played an integral role in introducing new drug therapies and medications to the depression drugs market in the U.S. For instance, in March 2019, the FDA approved a unique postpartum depression drugs that has offered promising results in clinical trials. Another major breakthrough in the depression drugs market is the approval of a nasal spray to address treatment-resistant depression. Similar such trends are expected to provide a notable boost to the overall growth of the depression drugs market during the assessment period.

Demand for Antidepressants Remains Steady amid COVID-19 Pandemic

The onset of the novel COVID-19 pandemic is expected to have an impact on the overall growth of the depression drugs market, as a large number of individuals suffering from mental health conditions is increasingly leaning toward prescription drugs such as benzodiazepines and antidepressants. In addition, as governments in several nations have imposed lockdowns as a preventive measure to contain the transmission of the novel coronavirus, the demand for antianxiety medications has witnessed a considerable growth. The number of prescriptions for antidepressants witnessed a noteworthy growth during the first two quarters of 2020 and the trend is likely to continue in the next two quarters of 2020.

depression drugs market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

The global depression drugs market is expected to grow at a sluggish CAGR of 2.3% during the forecast period. Much of the market growth can be attributed to ongoing research and development activities, development of novel non-pharmacologic and pharmacologic interventions, increase in the number of collaborations between research institutes and pharmaceutical companies, and most importantly the growing prevalence of mild to severe depression around the world. Market players should focus on improving the effectiveness of their drugs, along with minimizing the side effects of the same.  

Depression Drugs Market: Overview

  • Depression drugs are medications used to treat major depressive disorders, some anxiety disorders, chronic pain conditions, and to help manage some addictions. Common side effects of depression drugs include dry mouth, weight gain, dizziness, headaches, and sexual dysfunction.
  • According to an analysis by the National Center for Health Statistics, the percentage of the U.S. population aged over 12 who took depression drugs was 12.7% in October 2017. Most depression drugs are used to treat depression, while some are prescribed for other conditions.
  • The burden of depression is rising across the world. According to the WHO, more than 800,000 people commit suicide every year, and depression is the second leading cause of death in people aged 15 to 29. Major depressive disorder (MDD) affects nearly 121 million people globally. According to the WHO, an estimated 4.4% of the global population suffers from depressive disorders and 3.6% from anxiety disorder. The World Health Survey (WHS) conducted in 2013 indicated that the prevalence of depression in countries classified according to economic development was similar, with 6.0% in low-income countries and 7.6% in upper-middle-income countries. Rise in the number of cases and increase in awareness among patients about diagnosis and treatment of depression are likely to drive the global depression drugs market.

Surge in Awareness about Depression

  • Rise in awareness about mental illness and available treatments drives the global depression drugs market. A number of people do not truly understand mental illness.
  • Remote counselling is increasing in the U.K., with services such as TalkSpace and BetterHelp pairing individuals with counsellors who can offer support and guidance over text messages. In Finland, an online therapy service called Mental Health Hub was set up 10 years ago in light of how hard it was for patients in rural areas to get help. Rise in awareness and technological advancements in communicating with people are expected to augment the depression drugs market in the near future.

Market Segmentation: Depression Drugs Market

  • In terms of drug class, the global depression drugs market has been divided into selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, tricyclic antidepressants, and others
  • Based on disease type, the global depression drugs market has been classified into major depressive disorder, schizophrenia and bipolar I disorder, obsessive-compulsive disorders (OCD), anxiety disorder, and others
  • In terms of distribution channel, the global depression drugs market has been categorized into retail pharmacies, hospital pharmacies, and online pharmacies
  • Each of the segments has been analyzed in detail for market trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The depression drugs market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2018 to 2030, considering 2019 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment of the global depression drugs market from 2020 to 2030, along with market size estimations.

Regional Overview: Depression Drugs Market

  • In terms of region, the global depression drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • The current and future market sizes in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the depression drugs market report for the period from 2018 to 2030, along with their CAGRs for the period from 2020 to 2030
  • The study also offers a list of recommendations, highlights, and useful insights of the depression drugs market, which will help new companies willing to enter the market and existing companies to increase market share, and help in the decision-making process

Major Players

  • The report concludes with the company profiles section that includes key information about the major players in the depression drugs market
  • Leading players analyzed in the depression drugs market report are 
    • Johnson & Johnson
    • Otsuka Pharmaceutical Co., Ltd.,
    • Allergan
    • Novartis AG
    • Eli Lilly and Company
    • Takeda Pharmaceutical Company Limited
    • Abbott, Pfizer
    • GlaxoSmithKline
  • Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Depression Drugs Market - Segmentation

TMR’s study on the global depression drugs market includes information divided into four segments: drug class, disease type, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global depression drugs market have been discussed in detail.

Drug Class

  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
  • Atypical Antidepressants
  • Tricyclic Antidepressants
  • Others (CNS Stimulants, Monoamine Oxidase Inhibitors, etc.)

Disease Type

  • Major Depressive Disorder
  • Schizophrenia and Bipolar I Disorder
  • Obsessive-Compulsive Disorders (OCD)
  • Anxiety Disorder
  • Others (ADHD, SSRI-induced Disorder, etc.)

Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of Depression Drugs Market?

The global Depression Drugs Market was worth US$ 18.9 Bn and is projected to reach a value of US$ 24.3 Bn by the end of 2030

What is the anticipated CAGR of the Depression Drugs Market in the forecast period?

Depression Drugs Market is anticipated to grow at a CAGR of 2.3% during the forecast period

Which region is expected to project the highest market share in the global Depression Drugs Market?

North America accounted for a major share of the global Depression Drugs Market

What are the key driving factors for the growth of the Depression Drugs Market?

Rise in the number of cases and increase in awareness among patients about diagnosis and treatment of depression are likely to drive the global depression drugs market

Who are the key players in the global Depression Drugs Market?

Key players in the global Depression Drugs Market include Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Allergan, Novartis AG, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Abbott, Pfizer, GlaxoSmithKline

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Depression Drugs Market 

    4. Market Overview

        4.1.  Introduction & Overview

        4.2. Product Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities 

        4.4. Global Depression Drugs Market Analysis and Forecast, 2018–2030

    5. Market Outlook 

        5.1. Pipeline Analysis 

        5.2. Disease Prevalence & Incidence Rate globally with key countries

        5.3. Regulatory Scenario 

        5.4. Key Mergers & Acquisitions

    6. Global Depression Drugs Market Analysis and Forecast, by Drug Class

        6.1. Introduction & Definition

        6.2. Global Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            6.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            6.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            6.2.3. Atypical Antidepressants

            6.2.4. Tricyclic Antidepressants

            6.2.5.  Others

        6.3. Global Depression Drugs Market Attractiveness Analysis, by Drug Class

    7. Global Depression Drugs Market Analysis and Forecast, by Disease Type

        7.1. Introduction & Definition

        7.2. Global Depression Drugs Market Value (US$) Forecast, by Disease Type, 2018–2030

            7.2.1. Major Depressive Disorder 

            7.2.2. Schizophrenia and Bipolar I Disorder 

            7.2.3. Obsessive-Compulsive Disorders (OCD)

            7.2.4. Anxiety Disorder

            7.2.5. Others

        7.3. Global Depression Drugs Market Attractiveness Analysis, by Disease Type

    8. Global Depression Drugs Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Global Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            8.2.1. Hospital Pharmacies

            8.2.2. Retail Pharmacies

            8.2.3. Online Pharmacies

        8.3. Global Depression Drugs Market Attractiveness Analysis, by Distribution Channel

    9. Global Depression Drugs Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Global Depression Drugs Market Value (US$ Mn) Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Global Depression Drugs Market Attractiveness Analysis, by Region

    10. North America Depression Drugs Market Analysis and Forecast

        10.1. Introduction

        10.2. North America Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            10.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            10.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            10.2.3. Atypical Antidepressants

            10.2.4. Tricyclic Antidepressants

            10.2.5.  Others 

        10.3. North America Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            10.3.1. Major Depressive Disorder 

            10.3.2. Schizophrenia and Bipolar I Disorder 

            10.3.3. Obsessive-Compulsive Disorders (OCD)

            10.3.4. Anxiety Disorder

            10.3.5. Others

        10.4. North America Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            10.4.1. Hospital Pharmacies

            10.4.2. Retail Pharmacies

            10.4.3. Online Pharmacies

        10.5. North America Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

            10.5.1. U.S.

            10.5.2. Canada

        10.6. North America Depression Drugs Market Attractiveness Analysis

            10.6.1. By Drug Class

            10.6.2. By Disease Type

            10.6.3. By Distribution Channel

            10.6.4. By Country 

    11. U.S. Depression Drugs Market Analysis and Forecast

        11.1. Introduction

        11.2. U.S. Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            11.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            11.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            11.2.3. Atypical Antidepressants

            11.2.4. Tricyclic Antidepressants

            11.2.5.  Others 

        11.3. U.S. Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            11.3.1. Major Depressive Disorder 

            11.3.2. Schizophrenia and Bipolar I Disorder 

            11.3.3. Obsessive-Compulsive Disorders (OCD)

            11.3.4. Anxiety Disorder

            11.3.5. Others

        11.4. U.S. Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            11.4.1. Hospital Pharmacies

            11.4.2. Retail Pharmacies

            11.4.3. Online Pharmacies

        11.5. U.S. Depression Drugs Market Attractiveness Analysis

            11.5.1. By Drug Class

            11.5.2. By Disease Type

            11.5.3. By Distribution Channel

    12. Canada Depression Drugs Market Analysis and Forecast

        12.1. Introduction

        12.2. Canada Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            12.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            12.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            12.2.3. Atypical Antidepressants

            12.2.4. Tricyclic Antidepressants

            12.2.5.  Others 

        12.3. Canada Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            12.3.1. Major Depressive Disorder 

            12.3.2. Schizophrenia and Bipolar I Disorder 

            12.3.3. Obsessive-Compulsive Disorders (OCD)

            12.3.4. Anxiety Disorder

            12.3.5. Others

        12.4. Canada Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            12.4.1. Hospital Pharmacies

            12.4.2. Retail Pharmacies

            12.4.3. Online Pharmacies

        12.5. Canada Depression Drugs Market Attractiveness Analysis

            12.5.1. By Drug Class

            12.5.2. By Disease Type

            12.5.3. By Distribution Channel

    13. Europe Depression Drugs Market Analysis and Forecast

        13.1. Introduction

        13.2. Europe Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            13.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            13.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            13.2.3. Atypical Antidepressants

            13.2.4. Tricyclic Antidepressants

            13.2.5.  Others 

        13.3. Europe Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            13.3.1. Major Depressive Disorder 

            13.3.2. Schizophrenia and Bipolar I Disorder 

            13.3.3. Obsessive-Compulsive Disorders (OCD)

            13.3.4. Anxiety Disorder

            13.3.5. Others

        13.4. Europe Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            13.4.1. Hospital Pharmacies

            13.4.2. Retail Pharmacies

            13.4.3. Online Pharmacies

        13.5. Europe Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

            13.5.1. Germany

            13.5.2. U.K.

            13.5.3. France

            13.5.4. Spain

            13.5.5. Italy

            13.5.6. Rest of Europe

        13.6. Europe Depression Drugs Market Attractiveness Analysis

            13.6.1. By Drug Class

            13.6.2. By Disease Type

            13.6.3. By Distribution Channel

            13.6.4. By Country/Sub-region

    14. Germany Depression Drugs Market Analysis and Forecast

        14.1. Introduction

        14.2. Germany Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            14.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            14.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            14.2.3. Atypical Antidepressants

            14.2.4. Tricyclic Antidepressants

            14.2.5.  Others 

        14.3. Germany Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            14.3.1. Major Depressive Disorder 

            14.3.2. Schizophrenia and Bipolar I Disorder 

            14.3.3. Obsessive-Compulsive Disorders (OCD)

            14.3.4. Anxiety Disorder

            14.3.5. Others

        14.4. Germany Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            14.4.1. Hospital Pharmacies

            14.4.2. Retail Pharmacies

            14.4.3. Online Pharmacies

        14.5. Germany Depression Drugs Market Attractiveness Analysis

            14.5.1. By Drug Class

            14.5.2. By Disease Type

            14.5.3. By Distribution Channel

    15. France Depression Drugs Market Analysis and Forecast

        15.1. Introduction

        15.2. France Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            15.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            15.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            15.2.3. Atypical Antidepressants

            15.2.4. Tricyclic Antidepressants

            15.2.5.  Others 

        15.3. France Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            15.3.1. Major Depressive Disorder 

            15.3.2. Schizophrenia and Bipolar I Disorder 

            15.3.3. Obsessive-Compulsive Disorders (OCD)

            15.3.4. Anxiety Disorder

            15.3.5. Others

        15.4. France Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            15.4.1. Hospital Pharmacies

            15.4.2. Retail Pharmacies

            15.4.3. Online Pharmacies

        15.5. France Depression Drugs Market Attractiveness Analysis

            15.5.1. By Drug Class

            15.5.2. By Disease Type

            15.5.3. By Distribution Channel

    16. U.K. Depression Drugs Market Analysis and Forecast

        16.1. Introduction

        16.2. U.K. Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            16.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            16.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            16.2.3. Atypical Antidepressants

            16.2.4. Tricyclic Antidepressants

            16.2.5.  Others 

        16.3. U.K. Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            16.3.1. Major Depressive Disorder 

            16.3.2. Schizophrenia and Bipolar I Disorder 

            16.3.3. Obsessive-Compulsive Disorders (OCD)

            16.3.4. Anxiety Disorder

            16.3.5. Others

        16.4. U.K. Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            16.4.1. Hospital Pharmacies

            16.4.2. Retail Pharmacies

            16.4.3. Online Pharmacies

        16.5. U.K. Depression Drugs Market Attractiveness Analysis

            16.5.1. By Drug Class

            16.5.2. By Disease Type

            16.5.3. By Distribution Channel

    17. Italy Depression Drugs Market Analysis and Forecast

        17.1. Introduction

        17.2. Italy Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            17.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            17.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            17.2.3. Atypical Antidepressants

            17.2.4. Tricyclic Antidepressants

            17.2.5.  Others 

        17.3. Italy Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            17.3.1. Major Depressive Disorder 

            17.3.2. Schizophrenia and Bipolar I Disorder 

            17.3.3. Obsessive-Compulsive Disorders (OCD)

            17.3.4. Anxiety Disorder

            17.3.5. Others

        17.4. Italy Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            17.4.1. Hospital Pharmacies

            17.4.2. Retail Pharmacies

            17.4.3. Online Pharmacies

        17.5. Italy Depression Drugs Market Attractiveness Analysis

            17.5.1. By Drug Class

            17.5.2. By Disease Type

            17.5.3. By Distribution Channel

    18. Spain Depression Drugs Market Analysis and Forecast

        18.1. Introduction

        18.2. Spain Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            18.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            18.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            18.2.3. Atypical Antidepressants

            18.2.4. Tricyclic Antidepressants

            18.2.5.  Others 

        18.3. Spain Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            18.3.1. Major Depressive Disorder 

            18.3.2. Schizophrenia and Bipolar I Disorder 

            18.3.3. Obsessive-Compulsive Disorders (OCD)

            18.3.4. Anxiety Disorder

            18.3.5. Others

        18.4. Spain Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            18.4.1. Hospital Pharmacies

            18.4.2. Retail Pharmacies

            18.4.3. Online Pharmacies

        18.5. Spain Depression Drugs Market Attractiveness Analysis

            18.5.1. By Drug Class

            18.5.2. By Disease Type

            18.5.3. By Distribution Channel

    19. Asia Pacific Depression Drugs Market Analysis and Forecast

        19.1. Introduction

        19.2. Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            19.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            19.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            19.2.3. Atypical Antidepressants

            19.2.4. Tricyclic Antidepressants

            19.2.5.  Others 

        19.3. Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            19.3.1. Major Depressive Disorder 

            19.3.2. Schizophrenia and Bipolar I Disorder 

            19.3.3. Obsessive-Compulsive Disorders (OCD)

            19.3.4. Anxiety Disorder

            19.3.5. Others

        19.4. Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            19.4.1. Hospital Pharmacies

            19.4.2. Retail Pharmacies

            19.4.3. Online Pharmacies

        19.5. Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

            19.5.1. China

            19.5.2. Japan

            19.5.3. India

            19.5.4. Australia & New Zealand

            19.5.5. Rest of Asia Pacific

        19.6. Asia Pacific Depression Drugs Market Attractiveness Analysis

            19.6.1. By Drug Class

            19.6.2. By Disease Type

            19.6.3. By Distribution Channel

            19.6.4. By Country/Sub-region

    20. Japan Depression Drugs Market Analysis and Forecast

        20.1. Introduction

        20.2. Japan Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            20.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            20.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            20.2.3. Atypical Antidepressants

            20.2.4. Tricyclic Antidepressants

            20.2.5.  Others 

        20.3. Japan Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            20.3.1. Major Depressive Disorder 

            20.3.2. Schizophrenia and Bipolar I Disorder 

            20.3.3. Obsessive-Compulsive Disorders (OCD)

            20.3.4. Anxiety Disorder

            20.3.5. Others

        20.4. Japan Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            20.4.1. Hospital Pharmacies

            20.4.2. Retail Pharmacies

            20.4.3. Online Pharmacies

        20.5. Japan Depression Drugs Market Attractiveness Analysis

            20.5.1. By Drug Class

            20.5.2. By Disease Type

            20.5.3. By Distribution Channel

    21. China Depression Drugs Market Analysis and Forecast

        21.1. Introduction

        21.2. China Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            21.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            21.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            21.2.3. Atypical Antidepressants

            21.2.4. Tricyclic Antidepressants

            21.2.5.  Others 

        21.3. China Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            21.3.1. Major Depressive Disorder 

            21.3.2. Schizophrenia and Bipolar I Disorder 

            21.3.3. Obsessive-Compulsive Disorders (OCD)

            21.3.4. Anxiety Disorder

            21.3.5. Others

        21.4. China Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            21.4.1. Hospital Pharmacies

            21.4.2. Retail Pharmacies

            21.4.3. Online Pharmacies

        21.5. China Depression Drugs Market Attractiveness Analysis

            21.5.1. By Drug Class

            21.5.2. By Disease Type

            21.5.3. By Distribution Channel

    22. India Depression Drugs Market Analysis and Forecast

        22.1. Introduction

        22.2. India Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            22.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            22.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            22.2.3. Atypical Antidepressants

            22.2.4. Tricyclic Antidepressants

            22.2.5.  Others 

        22.3. India Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            22.3.1. Major Depressive Disorder 

            22.3.2. Schizophrenia and Bipolar I Disorder 

            22.3.3. Obsessive-Compulsive Disorders (OCD)

            22.3.4. Anxiety Disorder

            22.3.5. Others

        22.4. India Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            22.4.1. Hospital Pharmacies

            22.4.2. Retail Pharmacies

            22.4.3. Online Pharmacies

        22.5. India Depression Drugs Market Attractiveness Analysis

            22.5.1. By Drug Class

            22.5.2. By Disease Type

            22.5.3. By Distribution Channel

    23. Australia & New Zealand Depression Drugs Market Analysis and Forecast

        23.1. Introduction

        23.2. Australia & New Zealand Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            23.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            23.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            23.2.3. Atypical Antidepressants

            23.2.4. Tricyclic Antidepressants

            23.2.5.  Others 

        23.3. Australia & New Zealand Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            23.3.1. Major Depressive Disorder 

            23.3.2. Schizophrenia and Bipolar I Disorder 

            23.3.3. Obsessive-Compulsive Disorders (OCD)

            23.3.4. Anxiety Disorder

            23.3.5. Others

        23.4. Australia & New Zealand Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            23.4.1. Hospital Pharmacies

            23.4.2. Retail Pharmacies

            23.4.3. Online Pharmacies

        23.5. Australia & New Zealand Depression Drugs Market Attractiveness Analysis

            23.5.1. By Drug Class

            23.5.2. By Disease Type

            23.5.3. By Distribution Channel

    24. Latin America Depression Drugs Market Analysis and Forecast

        24.1. Introduction

        24.2. Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            24.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            24.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            24.2.3. Atypical Antidepressants

            24.2.4. Tricyclic Antidepressants

            24.2.5.  Others 

        24.3. Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            24.3.1. Major Depressive Disorder 

            24.3.2. Schizophrenia and Bipolar I Disorder 

            24.3.3. Obsessive-Compulsive Disorders (OCD)

            24.3.4. Anxiety Disorder

            24.3.5. Others

        24.4. Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            24.4.1. Hospital Pharmacies

            24.4.2. Retail Pharmacies

            24.4.3. Online Pharmacies

        24.5. Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

            24.5.1. Brazil

            24.5.2. Mexico

            24.5.3. Rest of Latin America

        24.6. Latin America Depression Drugs Market Attractiveness Analysis

            24.6.1. By Drug Class

            24.6.2. By Disease Type

            24.6.3. By Distribution Channel

            24.6.4. By Country/Sub-region

    25. Brazil Depression Drugs Market Analysis and Forecast

        25.1. Introduction

        25.2. Brazil Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            25.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            25.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            25.2.3. Atypical Antidepressants

            25.2.4. Tricyclic Antidepressants

            25.2.5.  Others 

        25.3. Brazil Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            25.3.1. Major Depressive Disorder 

            25.3.2. Schizophrenia and Bipolar I Disorder 

            25.3.3. Obsessive-Compulsive Disorders (OCD)

            25.3.4. Anxiety Disorder

            25.3.5. Others

        25.4. Brazil Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            25.4.1. Hospital Pharmacies

            25.4.2. Retail Pharmacies

            25.4.3. Online Pharmacies

        25.5. Brazil Depression Drugs Market Attractiveness Analysis

            25.5.1. By Drug Class

            25.5.2. By Disease Type

            25.5.3. By Distribution Channel

    26. Mexico Depression Drugs Market Analysis and Forecast

        26.1. Introduction

        26.2. Mexico Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            26.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            26.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            26.2.3. Atypical Antidepressants

            26.2.4. Tricyclic Antidepressants

            26.2.5.  Others 

        26.3. Mexico Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            26.3.1. Major Depressive Disorder 

            26.3.2. Schizophrenia and Bipolar I Disorder 

            26.3.3. Obsessive-Compulsive Disorders (OCD)

            26.3.4. Anxiety Disorder

            26.3.5. Others

        26.4. Mexico Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            26.4.1. Hospital Pharmacies

            26.4.2. Retail Pharmacies

            26.4.3. Online Pharmacies

        26.5. Mexico Depression Drugs Market Attractiveness Analysis

            26.5.1. By Drug Class

            26.5.2. By Disease Type

            26.5.3. By Distribution Channel

    27. Middle East & Africa Depression Drugs Market Analysis and Forecast

        27.1. Introduction

        27.2. Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            27.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            27.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            27.2.3. Atypical Antidepressants

            27.2.4. Tricyclic Antidepressants

            27.2.5.  Others 

        27.3. Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            27.3.1. Major Depressive Disorder 

            27.3.2. Schizophrenia and Bipolar I Disorder 

            27.3.3. Obsessive-Compulsive Disorders (OCD)

            27.3.4. Anxiety Disorder

            27.3.5. Others

        27.4. Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            27.4.1. Hospital Pharmacies

            27.4.2. Retail Pharmacies

            27.4.3. Online Pharmacies

        27.5. Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

            27.5.1. GCC Countries

            27.5.2. South Africa

            27.5.3. Rest of Middle East & Africa

        27.6. Middle East & Africa Depression Drugs Market Attractiveness Analysis

            27.6.1. By Drug Class

            27.6.2. By Disease Type

            27.6.3. By Distribution Channel

            27.6.4. By Country/Sub-region

    28. GCC Countries Depression Drugs Market Analysis and Forecast

        28.1. Introduction

        28.2. GCC Countries Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            28.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            28.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            28.2.3. Atypical Antidepressants

            28.2.4. Tricyclic Antidepressants

            28.2.5.  Others 

        28.3. GCC Countries Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            28.3.1. Major Depressive Disorder 

            28.3.2. Schizophrenia and Bipolar I Disorder 

            28.3.3. Obsessive-Compulsive Disorders (OCD)

            28.3.4. Anxiety Disorder

            28.3.5. Others

        28.4. GCC Countries Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            28.4.1. Hospital Pharmacies

            28.4.2. Retail Pharmacies

            28.4.3. Online Pharmacies

        28.5. GCC Countries Depression Drugs Market Attractiveness Analysis

            28.5.1. By Drug Class

            28.5.2. By Disease Type

            28.5.3. By Distribution Channel

    29. South Africa Depression Drugs Market Analysis and Forecast

        29.1. Introduction

        29.2. South Africa Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            29.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

            29.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

            29.2.3. Atypical Antidepressants

            29.2.4. Tricyclic Antidepressants

            29.2.5.  Others 

        29.3. South Africa Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

            29.3.1. Major Depressive Disorder 

            29.3.2. Schizophrenia and Bipolar I Disorder 

            29.3.3. Obsessive-Compulsive Disorders (OCD)

            29.3.4. Anxiety Disorder

            29.3.5. Others

        29.4. South Africa Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            29.4.1. Hospital Pharmacies

            29.4.2. Retail Pharmacies

            29.4.3. Online Pharmacies

        29.5. South Africa Depression Drugs Market Attractiveness Analysis

            29.5.1. By Drug Class

            29.5.2. By Disease Type

            29.5.3. By Distribution Channel

    30. Competition Landscape

        30.1. Competition Matrix

        30.2. Market Share Analysis, by Company, 2019

        30.3. Company Profiles

            30.3.1. Novartis AG 

                30.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                30.3.1.2. Company Financials

                30.3.1.3. Growth Strategies

                30.3.1.4. SWOT Analysis

            30.3.2. GlaxoSmithKline plc 

                30.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                30.3.2.2. Company Financials

                30.3.2.3. Growth Strategies

                30.3.2.4. SWOT Analysis

            30.3.3. Eli Lilly and Company 

                30.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                30.3.3.2. Company Financials

                30.3.3.3. Growth Strategies

                30.3.3.4. SWOT Analysis

            30.3.4. Pfizer, Inc. 

                30.3.4.1. Company Overview (HQ, Business Segments)

                30.3.4.2. Company Financials

                30.3.4.3. Growth Strategies

                30.3.4.4. SWOT Analysis

            30.3.5. Allergan plc

                30.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                30.3.5.2. Company Financials

                30.3.5.3. Growth Strategies

                30.3.5.4. SWOT Analysis

            30.3.6. Takeda Pharmaceutical Company Limited

                30.3.6.1. Company Overview (HQ, Business Segments)

                30.3.6.2. Company Financials

                30.3.6.3. Growth Strategies

                30.3.6.4. SWOT Analysis

            30.3.7. AstraZeneca plc 

                30.3.7.1. Company Overview (HQ, Business Segments)

                30.3.7.2. Company Financials

                30.3.7.3. Growth Strategies

                30.3.7.4. SWOT Analysis

            30.3.8. Johnson & Johnson 

                30.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                30.3.8.2. Company Financials

                30.3.8.3. Growth Strategies

                30.3.8.4. SWOT Analysis

            30.3.9. Abbott 

                30.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                30.3.9.2. Company Financials

                30.3.9.3. Growth Strategies

                30.3.9.4. SWOT Analysis

            30.3.10. Otsuka Pharmaceutical Co., Ltd. 

                30.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                30.3.10.2. Company Financials

                30.3.10.3. Growth Strategies

                30.3.10.4. SWOT Analysis

    List of Tables

    Table 01: Global Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 02: Global Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 03: Global Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 04: Global Depression Drugs Market Value (US$ Mn) Forecast, by Region, 2018–2030

    Table 05: North America Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 06: North America Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 07: North America Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 08: North America Depression Drugs Market Value (US$ Mn) Forecast, by Country, 2018–2030

    Table 09: U.S. Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 10: U.S. Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 11: U.S. Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 12: Canada Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 13: Canada Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 14: Canada Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 15: Europe Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 16: Europe Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 17: Europe Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 18: Europe Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 19: U.K. Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 20: U.K. Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 21: U.K. Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 22: Spain Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 23: Spain Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 24: Spain Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 25: Germany Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 26: Germany Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 27: Germany Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 28: France Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 29: France Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 30: France Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 31: Italy Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 32: Italy Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 33: Italy Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 34: Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 35: Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 36: Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 37: Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 38: Japan Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 39: Japan Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 40: Japan Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 41: China Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 42: China Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 43: China Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 44: India Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 45: India Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 46: India Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 47: Australia & New Zealand Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 48: Australia & New Zealand Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 49: Australia & New Zealand Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 50: Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 51: Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 52: Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 53: Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2018–2030

    Table 54: Brazil Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 55: Brazil Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 56: Brazil Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 57: Mexico Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 58: Mexico Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 59: Mexico Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 60: Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 61: Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 62: Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 63: Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2018–2030

    Table 64: GCC Countries Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 65: GCC Countries Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 66: GCC Countries Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 67: South Africa Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 68: South Africa Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 69: South Africa Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    List of Figures

    Figure 01: Global Depression Drugs Market Value (US$ Mn) and Distribution (%), by Region, 2019 and 2030

    Figure 02: Global Depression Drugs Market Value (US$ Mn) Forecast, 2018–2030

    Figure 03: Market Value Share, by Drug Class, 2019

    Figure 04: Market Value Share, by Disease Type, 2019

    Figure 05: Market Value Share, by Distribution Channel, 2019

    Figure 06: Market Value Share, by Region, 2019

    Figure 07: Global Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 08: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by SSRIs, 2018–2030

    Figure 09: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by SNRIs, 2018–2030 

    Figure 10: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Atypical Antidepressants, 2018–2030

    Figure 11: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Tricyclic Antidepressants, 2018–2030 

    Figure 12: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2018–2030

    Figure 13: Global Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 14: Global Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 15: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Major Depressive Disorder, 2018–2030

    Figure 16: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Schizophrenia and Bipolar I Disorder, 2018–2030 

    Figure 17: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Obsessive Compulsive Disorder (OCD), 2018–2030

    Figure 18: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Anxiety Disorder, 2018–2030 

    Figure 19: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2018–2030

    Figure 20: Global Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 21: Global Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 22: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2018–2030

    Figure 23: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2018–2030 

    Figure 24: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2018–2030

    Figure 25: Global Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 26: Global Depression Drugs Market, by Region, 2019 and 2030

    Figure 27: Global Depression Drugs Market Attractiveness Analysis, by Region, 2020–2030

    Figure 28: North America Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 29: North America Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 30: North America Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 31: North America Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 32: North America Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 33: North America Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 34: North America Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 35: North America Depression Drugs Market Value Share Analysis, by Country, 2019 and 2030

    Figure 36: North America Depression Drugs Market Attractiveness Analysis, by Country, 2020–2030

    Figure 37: U.S. Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 38: U.S. Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 39: U.S. Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 40: U.S. Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 41: U.S. Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 42: U.S. Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 43: U.S. Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 44: Canada Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 45: Canada Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 46: Canada Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 47: Canada Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 48: Canada Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 49: Canada Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 50: Canada Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 51: Europe Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 52: Europe Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 53: Europe Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 54: Europe Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 55: Europe Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 56: Europe Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 57: Europe Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 58: Europe Depression Drugs Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 59: Europe Depression Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 60: U.K. Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 61: U.K. Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 62: U.K. Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 63: U.K. Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 64: U.K. Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 65: U.K. Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 66: U.K. Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 67: Spain Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 68: Spain Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 69: Spain Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 70: Spain Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 71: Spain Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 72: Spain Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 73: Spain Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 74: Germany Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 75: Germany Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 76: Germany Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 77: Germany Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 78: Germany Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 79: Germany Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 80: Germany Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 81: France Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 82: France Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 83: France Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 84: France Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 85: France Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 86: France Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 87: France Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 88: Italy Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 89: Italy Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 90: Italy Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 91: Italy Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 92: Italy Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 93: Italy Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 94: Italy Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 95: Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 96: Asia Pacific Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 97: Asia Pacific Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 99: Asia Pacific Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 100: Asia Pacific Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 101: Asia Pacific Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 102: Asia Pacific Depression Drugs Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 103: Asia Pacific Depression Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 104: Japan Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 105: Japan Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 106: Japan Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 107: Japan Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 108: Japan Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 109: Japan Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 110: Japan Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 111: China Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 112: China Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 113: China Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 114: China Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 115: China Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 116: China Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 117: China Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 118: India Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 119: India Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 120: India Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 121: India Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 122: India Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 123: India Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 124: India Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 125: Australia & New Zealand Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 126: Australia & New Zealand Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 127: Australia & New Zealand Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 128: Australia & New Zealand Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 129: Australia & New Zealand Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 130: Australia & New Zealand Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 131: Australia & New Zealand Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 132: Latin America Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 133: Latin America Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 134: Latin America Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 135: Latin America Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 136: Latin America Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 137: Latin America Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 138: Latin America Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 139: Latin America Depression Drugs Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 140: Latin America Depression Drugs Market Attractiveness Analysis, by Country /Sub-region, 2020–2030

    Figure 141: Brazil Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 142: Brazil Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 143: Brazil Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 144: Brazil Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 145: Brazil Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 146: Brazil Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 147: Brazil Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 148: Mexico Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 149: Mexico Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 150: Mexico Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 151: Mexico Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 152: Mexico Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 153: Mexico Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 154: Mexico Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 155: Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 156: Middle East & Africa Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 157: Middle East & Africa Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 158: Middle East & Africa Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 159: Middle East & Africa Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 160: Middle East & Africa Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 161: Middle East & Africa Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 162: Middle East & Africa Depression Drugs Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 163: Middle East & Africa Depression Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 164: GCC Countries Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 165: GCC Countries Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 166: GCC Countries Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 167: GCC Countries Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 168: GCC Countries Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 169: GCC Countries Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 170: GCC Countries Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 171: South Africa Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 172: South Africa Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 173: South Africa Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 174: South Africa Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 175: South Africa Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 176: South Africa Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 177: South Africa Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Copyright © Transparency Market Research, Inc. All Rights reserved